E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Jordaan, Gwen ^a   Liao, Wei ^a   Sharma, Sanjai ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aberrant splicing; Chromatin modeling; CLL; E cadherin; HDAC inhibitors; Nonsense mediated decay; Wnt pathway

Indexed keywords

BETA CATENIN; CYCLIN D1; ENTINOSTAT; HISTONE; HISTONE H3; HISTONE H4; RNA; TRANSCRIPTION FACTOR; UVOMORULIN; WNT PROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYCLIN D1 GENE; DOWN REGULATION; E CADHERIN GENE; EPIGENETICS; EXON; GENE; GENE EXPRESSION; GENE REEXPRESSION; GENE SILENCING; GENE TARGETING; HISTONE ACETYLATION; HISTONE HYPOACETYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LEF GENE; LEUKEMIA CELL LINE; LEUKEMOGENESIS; NONSENSE MEDIATED MRNA DECAY; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLICING DEFECT; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CADHERINS; EPIGENOMICS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; TUMOR CELLS, CULTURED; WNT SIGNALING PATHWAY;

EID: 84874162273     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-88     Document Type: Article

References (55)

1. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303(5663):1483-1487. 10.1126/science.1094291, 3372896, 15001769.
2. Polakis P. Wnt Signaling in Cancer. Cold Spring Harb Perspect Biol 2012, 4(5):1-13.
3. Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol 2010, 3:33. 10.1186/1756-8722-3-33, 2954871, 20843302.
4. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004, 101(9):3118-3123. 10.1073/pnas.0308648100, 365753, 14973184.
5. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 2006, 66(2):653-658. 10.1158/0008-5472.CAN-05-3712, 16423993.
6. Chim CS, Pang R, Liang R. Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia. J Clin Pathol 2008, 61(11):1214-1219. 10.1136/jcp.2008.060152, 18765431.
7. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT. Identification of c-MYC as a target of the APC pathway. Science 1998, 281(5382):1509-1512.
8. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001, 28(1):53-57.
9. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398(6726):422-426. 10.1038/18884, 10201372.
10. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AM. Transcriptionalactivationofcyclooxygenase-2inWnt-1-transformed mouse mammary epithelial cells. Cancer Res 1999, 59(7):1572-1577.
11. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999, 155(4):1033-1038. 10.1016/S0002-9440(10)65204-2, 1867011, 10514384.
12. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci 1999, 112(Pt 8):1237-1245.
13. Sadot E, Simcha I, Shtutman M, Ben-Ze'ev A, Geiger B. Inhibition of beta- catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci USA 1998, 95(26):15339-15344. 10.1073/pnas.95.26.15339, 28044, 9860970.
14. Sharma S, Lichtenstein A. Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood 2009, 114(19):4179-4185. 10.1182/blood-2009-03-206482, 2774554, 19745069.
15. Gandhirajan RK, Poll-Wolbeck SJ, Gehrke I, Kreuzer KA. Wnt/beta- catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options. Curr Cancer Drug Targets 2010, 10(7):716-727. 10.2174/156800910793605794, 20578984.
16. Verkaar F, Zaman GJ. New avenues to target Wnt/beta-catenin signaling. Drug Discov Today 2011, 16(1-2):35-41.
17. Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 2011, 3(5):581-609. 10.2217/epi.11.73, 22126248.
18. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010, 31(1):27-36. 10.1093/carcin/bgp220, 2802667, 19752007.
19. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119(5):1162-1172.
20. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009, 8(6):1409-1420. 10.1158/1535-7163.MCT-08-0860, 19509247.
21. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27(32):5459-5468. 10.1200/JCO.2009.22.1291, 19826124.
22. Berger SL, Felsenfeld G. Chromatin goes global. Mol Cell 2001, 8(2):263-268. 10.1016/S1097-2765(01)00330-6, 11545729.
23. Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011, 81(5-6):325-329.
24. Bokelmann I, Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 2008, 14(1-2):20-27. 2047630, 17973028.
25. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009, 147(4):507-514. 10.1111/j.1365-2141.2009.07881.x, 2779118, 19747365.
26. El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010, 9(5):1349-1360. 10.1158/1535-7163.MCT-09-1000, 20406947.
27. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 2007, 76:51-74. 10.1146/annurev.biochem.76.050106.093909, 17352659.
28. Noensie EN, Dietz HC. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat Biotechnol 2001, 19(5):434-439. 10.1038/88099, 11329012.
29. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(9):e45. 10.1093/nar/29.9.e45, 55695, 11328886.
30. Kornblihtt AR. Chromatin, transcript elongation and alternative splicing. Nat Struct Mol Biol 2006, 13(1):5-7. 10.1038/nsmb0106-5, 16395314.
31. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell 2011, 144(1):16-26. 10.1016/j.cell.2010.11.056, 3038581, 21215366.
32. Hnilicova J, Hozeifi S, Duskova E, Icha J, Tomankova T, Stanek D. Histone deacetylase activity modulates alternative splicing. PLoS One 2011, 6(2):e16727. 10.1371/journal.pone.0016727, 3032741, 21311748.
33. Zhou Y, Lu Y, Tian W. Epigenetic features are significantly associated with alternative splicing. BMC Genomics 2012, 13(1):123. 10.1186/1471-2164-13-123, 3362759, 22455468.
34. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood 2000, 95(10):3208-3213.
35. Schwartz S, Ast G. Chromatin density and splicing destiny: on the cross-talk between chromatin structure and splicing. EMBO J 2010, 29(10):1629-1636. 10.1038/emboj.2010.71, 2876972, 20407423.
36. Dhami P, Saffrey P, Bruce AW, Dillon SC, Chiang K, Bonhoure N. Complex exon-intron marking by histone modifications is not determined solely by nucleosome distribution. PLoS One 2010, 5(8):e12339. 10.1371/journal.pone.0012339, 2925886, 20808788.
37. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z. High- resolution profiling of histone methylations in the human genome. Cell 2007, 129(4):823-837. 10.1016/j.cell.2007.05.009, 17512414.
38. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008, 40(12):1413-1415. 10.1038/ng.259, 18978789.
39. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456(7221):470-476. 10.1038/nature07509, 2593745, 18978772.
40. Venables JP. Unbalanced alternative splicing and its significance in cancer. BioEssays 2006, 28(4):378-386. 10.1002/bies.20390, 16547952.
41. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010, 24(21):2343-2364. 10.1101/gad.1973010, 2964746, 21041405.
42. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 1999, 17(11):1097-1100. 10.1038/15079, 10545916.
43. Sharma S, Liao W, Zhou X, Wong DT, Lichtenstein A. Exon 11 skipping of E- cadherin RNA downregulates its expression in head and neck cancer cells. Mol Cancer Ther 2011, 10(9):1751-1759. 10.1158/1535-7163.MCT-11-0248, 3170438, 21764905.
44. Cramer P, Pesce CG, Baralle FE, Kornblihtt AR. Functional association between promoter structure and transcript alternative splicing. Proc Natl Acad Sci USA 1997, 94(21):11456-11460. 10.1073/pnas.94.21.11456, 23504, 9326631.
45. Cramer P, Caceres JF, Cazalla D, Kadener S, Muro AF, Baralle FE, Kornblihtt AR. Coupling of transcription with alternative splicing: RNA pol II promoters modulate SF2/ASF and 9G8 effects on an exonic splicing enhancer. Mol Cell 1999, 4(2):251-258. 10.1016/S1097-2765(00)80372-X, 10488340.
46. Kornblihtt AR. Promoter usage and alternative splicing. Curr Opin Cell Biol 2005, 17(3):262-268. 10.1016/j.ceb.2005.04.014, 15901495.
47. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011, 365(26):2497-2506. 10.1056/NEJMoa1109016, 22150006.
48. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011, 118(26):6904-6908. 10.1182/blood-2011-08-373159, 3245210, 22039264.
49. Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L, Stamatopoulos B. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 2012, 7(12):1403-1412. 10.4161/epi.22674, 3528695, 23108383.
50. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003, 3(1):17. 270068, 14613514.
51. Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 2002, 100(3):982-990. 10.1182/blood.V100.3.982, 12130512.
52. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002, 99(10):6955-6960. 10.1073/pnas.102181599, 124510, 12011454.
53. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010, 5(6):e10941. 10.1371/journal.pone.0010941, 2880605, 20532179.
54. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105(3):959-967.
55. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117(22):5827-4. 10.1182/blood-2010-10-312603, 3112033, 21355097.